Miracor Building Commercial Platform on Solid Clinical Foundations in the UK

Miracor Medical, with its clever, and novel PICSO® system for treating myocardial infarction (MI) patient, is keen to tell us how well things are going in the UK. As it is indeed a clever and novel concept, and as we’ve followed it in the past, we’re keen to listen.

Background

The Miracor PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System is designed to treat acute ST-Segment Elevation Myocardial Infarction (‘STEMI’) patients and less severe Non-ST-Segment Elevation Myocardial Infarction (‘NSTEMI’) patients by improving myocardial perfusion in complement with percutaneous coronary intervention (PCI). PICSO is applied during PCI and designed to intermittently block the coronary sinus, a large vessel that collects blood from the heart muscle (myocardium), thereby increasing perfusion of the myocardium and reducing injury resulting from myocardial infarction.

Miracor Medical Systems says it will further increase its activities in the UK, starting with its commitment to a direct sales subsidiary.

To date, several leading centers in the UK are already actively using the PICSO Impulse System to treat patients with MI. The company is currently conducting two clinical studies in the UK, further evaluating the effectiveness of PICSO Therapy in myocardial infarction patients, used in daily clinical practice during standard Percutaneous Coronary Intervention (PCI). Miracor points to recently presented data showing that PICSO, as an adjuvant treatment to primary PCI, may significantly reduce infarct size in patients presenting with acute ST-Segment Elevation Myocardial Infarction (STEMI).

The ‘PICSO in STEMI’ study is currently conducted at the Freeman Hospital in Newcastle upon Tyne (Prof. Dr. Azfar Zaman, Dr. Mohaned Egred), the Liverpool Heart and Chest Hospital (Dr. Nick Palmer), and Northern General Hospital, Sheffield (Dr. Ever Grech).

Investigator comments

Prof. Zaman, Chief Investigator of the “PICSO in STEMI” study stated; “The study is designed to explore the improvement of microvascular perfusion and cardiac function in acute myocardial infarction patients which remains a large unmet need. PICSO can be applied during PCI even in the acute setting and therefore has the potential to change the way we currently treat such patients and thereby improve outcomes in this huge patient population.”

The ‘PICSO in NSTEMI’ study is a Physician Initiated Study by Dr. Piers Clifford at the Wycombe Hospital in High Wycombe, Buckinghamshire. It evaluates the effectiveness of PICSO in patients with less severe, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI).

Talking about that study, Dr Clifford said; “Microvascular obstruction (MVO), which is very common in STEMI patients can also be observed in the NSTEMI patient population. PICSO has shown to reduce MVO in STEMI patients and we therefore are convinced that PICSO may also represent a useful intervention in this even larger patient population, with the potential to improve patient prognosis and reduce healthcare expenditure.”

Company comments 

“We are very pleased to see how quickly our therapy for acute MI patients has been integrated into the clinical setting,” says Ludwig Gold, CEO of Miracor Medical Systems; “With our newly founded subsidiary, we will be able to directly serve our UK customer base and enlarge our activities in this key market”.

Source: Business Wire

Share your thoughts

Your email address will not be published. Required fields are marked *